No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PROK240517C5000
- 0.15
- +0.05+50.00%
15min DelayTrading May 15 10:08 ET
0.30High0.10Low
0.15Open0.10Pre Close23 Volume142 Open Interest5.00Strike Price495.00Turnover367.66%IV30.00%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.15Time Value100Contract SizeAmericanOptions Type0.2479Delta0.2698Gamma26.41Leverage Ratio-0.0775Theta0.0001Rho6.55Eff Leverage0.0010Vega
Intraday
- 5D
- 1D
News
ProKidney, Sunnova and Big Lots All Gain 25%+ as Wall Street's Meme-Stock Craze Spreads
Wall Street's meme-stock madness extended to more companies Tuesday.
JAN, MTC and PROK Among Mid-day Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersDelcath Systems (NASDAQ:DCTH) stock rose 33.2% to $7.19 during Tuesday's regular session. The company's market cap stands at $199.8 million. As per the news, the Q1 earnings report came out tod
Express News | Shares of 'Meme Stocks' and High-short Interest Stocks Are Trading Higher Amid a Renewed Surge in the Space After Popular Retail Trader 'Roaring Kitty' Returned to Social Media
Here's Why We're Not Too Worried About ProKidney's (NASDAQ:PROK) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring
Stocks With More Than 10% Short Interest - Finviz Screener
Comments
Wall Street's meme-stock madness extended to more companies Tuesday, with $ProKidney(PROK.US$ and other names rising more than 25% despite no apparent news.
ProKidney -- a volatile biotech that's developing kidney-disease treatments – gained 33.8% to close at $4.12 even though the company had no news or other no obvious catalysts for the rally.
The stock has had a volatile history ever since going public in 2...
ProKidney -- a volatile biotech that's developing kidney-disease treatments – gained 33.8% to close at $4.12 even though the company had no news or other no obvious catalysts for the rally.
The stock has had a volatile history ever since going public in 2...
6
2
$ProKidney(PROK.US$ sank more than 15% Thursday as the biotech snapped a five-session winning streak that saw its price rise some 130% in just days.
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...
7
$ProKidney(PROK.US$ rose more than 30% Tuesday as the biotech firm rallied for the fourth straight session – a run-up that's seen the stock rise nearly 90% in less than a week.
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $Vertex Pharmaceuticals(VRTX.US$ unveiled plans to buy biotech $Alpine Immune(ALPN.US$ for $4.9 ...
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $Vertex Pharmaceuticals(VRTX.US$ unveiled plans to buy biotech $Alpine Immune(ALPN.US$ for $4.9 ...
4
Read more
420247365 : Blllllllocked mfr
JCBF : Been held down and shorted